-
Je něco špatně v tomto záznamu ?
Memory T cells: promising biomarkers for evaluating protection and vaccine efficacy against leishmaniasis
M. Nateghi-Rostami, Y. Sohrabi
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, přehledy
NLK
Directory of Open Access Journals
od 2010
Free Medical Journals
od 2010
PubMed Central
od 2010
Europe PubMed Central
od 2010
Open Access Digital Library
od 2010-01-01
Open Access Digital Library
od 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2010
- MeSH
- biologické markery MeSH
- CD4-pozitivní T-lymfocyty MeSH
- leishmanióza kožní * MeSH
- lidé MeSH
- paměťové T-buňky MeSH
- účinnost vakcíny MeSH
- vakcíny * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Understanding the immune response to Leishmania infection and identifying biomarkers that correlate with protection are crucial for developing effective vaccines. One intriguing aspect of Leishmania infection is the persistence of parasites, even after apparent lesion healing. Various host cells, including dendritic cells, fibroblasts, and Langerhans cells, may serve as safe sites for latent infection. Memory T cells, especially tissue-resident memory T cells (TRM), play a crucial role in concomitant immunity against cutaneous Leishmania infections. These TRM cells are long-lasting and can protect against reinfection in the absence of persistent parasites. CD4+ TRM cells, in particular, have been implicated in protection against Leishmania infections. These cells are characterized by their ability to reside in the skin and rapidly respond to secondary infections by producing cytokines such as IFN-γ, which activates macrophages to kill parasites. The induction of CD4+ TRM cells has shown promise in experimental immunization, leading to protection against Leishmania challenge infections. Identifying biomarkers of protection is a critical step in vaccine development and CD4+ TRM cells hold potential as biomarkers, as their presence and functions may correlate with protection. While recent studies have shown that Leishmania-specific memory CD4+ T-cell subsets are present in individuals with a history of cutaneous leishmaniasis, further studies are needed to characterize CD4+ TRM cell populations. Overall, this review highlights the importance of memory T cells, particularly skin-resident CD4+ TRM cells, as promising targets for developing effective vaccines against leishmaniasis and as biomarkers of immune protection to assess the efficacy of candidate vaccines against human leishmaniasis.
Department of Medical Genetics 3rd Faculty of Medicine Charles University Prague Czechia
Department of Parasitology Pasteur Institute of Iran Tehran Iran
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24007052
- 003
- CZ-PrNML
- 005
- 20240423155710.0
- 007
- ta
- 008
- 240412e20240226sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fimmu.2024.1304696 $2 doi
- 035 __
- $a (PubMed)38469319
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Nateghi-Rostami, Mahmoud $u Department of Parasitology, Pasteur Institute of Iran, Tehran, Iran
- 245 10
- $a Memory T cells: promising biomarkers for evaluating protection and vaccine efficacy against leishmaniasis / $c M. Nateghi-Rostami, Y. Sohrabi
- 520 9_
- $a Understanding the immune response to Leishmania infection and identifying biomarkers that correlate with protection are crucial for developing effective vaccines. One intriguing aspect of Leishmania infection is the persistence of parasites, even after apparent lesion healing. Various host cells, including dendritic cells, fibroblasts, and Langerhans cells, may serve as safe sites for latent infection. Memory T cells, especially tissue-resident memory T cells (TRM), play a crucial role in concomitant immunity against cutaneous Leishmania infections. These TRM cells are long-lasting and can protect against reinfection in the absence of persistent parasites. CD4+ TRM cells, in particular, have been implicated in protection against Leishmania infections. These cells are characterized by their ability to reside in the skin and rapidly respond to secondary infections by producing cytokines such as IFN-γ, which activates macrophages to kill parasites. The induction of CD4+ TRM cells has shown promise in experimental immunization, leading to protection against Leishmania challenge infections. Identifying biomarkers of protection is a critical step in vaccine development and CD4+ TRM cells hold potential as biomarkers, as their presence and functions may correlate with protection. While recent studies have shown that Leishmania-specific memory CD4+ T-cell subsets are present in individuals with a history of cutaneous leishmaniasis, further studies are needed to characterize CD4+ TRM cell populations. Overall, this review highlights the importance of memory T cells, particularly skin-resident CD4+ TRM cells, as promising targets for developing effective vaccines against leishmaniasis and as biomarkers of immune protection to assess the efficacy of candidate vaccines against human leishmaniasis.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a CD4-pozitivní T-lymfocyty $7 D015496
- 650 _2
- $a paměťové T-buňky $7 D000091246
- 650 _2
- $a účinnost vakcíny $7 D000087507
- 650 12
- $a leishmanióza kožní $7 D016773
- 650 12
- $a vakcíny $7 D014612
- 650 _2
- $a biologické markery $7 D015415
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Sohrabi, Yahya $u Department of Cardiology I-Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Münster, Westfälische Wilhelms-Universität, Münster, Germany $u Department of Medical Genetics, Third Faculty of Medicine, Charles University, Prague, Czechia
- 773 0_
- $w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 15 (20240226), s. 1304696
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38469319 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423155707 $b ABA008
- 999 __
- $a ok $b bmc $g 2081201 $s 1216819
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 15 $c - $d 1304696 $e 20240226 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
- LZP __
- $a Pubmed-20240412